Discover
IMVT
Immunovant, Inc.
38.14
2 x 27.47
2 x 48.87
bid
ask
-
0.39
1.01%
2 @ 04:00 PM
38.05 -0.09 (0.24%)
| Ytd | 50.04% | |
| 1y | 136.16% |
37.74
day range
38.87
14.32
52 week range
39.28
| Open | 38.39 | Prev Close | 38.53 | Low | 37.74 | High | 38.87 | Mkt Cap | 7.83B |
| Vol | 828.85K | Avg Vol | 1.95M | EPS | -2.77 | P/E | N/A | Forward P/E | -15.81 |
| Beta | 0.79 | Short Ratio | 7.73 | Inst. Own | 54.74% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-10 | 50-d Avg | 31.78 | 200-d Avg | 25.60 | 1yr Est | 45.76 |
| Income Statement | |||
| Operating Expenses | 159.55M | ||
| Research and Development Expense | 142.29M | ||
| Selling, General and Administrative Expense | 17.27M | ||
| Operating Income | -159.55M | ||
| Income Tax Expense | -2.84M | ||
| Net Income | -147.86M | ||
| Net Income Common Stock | -147.86M | ||
| Net Income Common Stock (USD) | -147.86M | ||
| Consolidated Income | -147.86M | ||
| Earnings per Basic Share | -0.73 | ||
| Earnings per Basic Share (USD) | -0.73 | ||
| Earnings per Diluted Share | -0.73 | ||
| Earning Before Interest & Taxes (EBIT) | -150.70M | ||
| Earning Before Interest & Taxes (USD) | -150.70M | ||
| Weighted Average Shares | 203.44M | ||
| Weighted Average Shares Diluted | 203.44M | ||
| Balance Sheet | |||
| Cash and Equivalents | 902.11M | ||
| Cash and Equivalents (USD) | 902.11M | ||
| Trade and Non-Trade Receivables | 1.13M | ||
| Current Assets | 948.82M | ||
| Property, Plant & Equipment Net | 515.00K | ||
| Total Assets | 957.01M | ||
| Debt Current | 72.00K | ||
| Total Debt | 72.00K | ||
| Current Liabilities | 104.42M | ||
| Total Liabilities | 104.42M | ||
| Accumulated Retained Earnings (Deficit) | -1.75B | ||
| Accumulated Other Comprehensive Income | 730.00K | ||
| Shareholders Equity | 852.59M | ||
| Shareholders Equity (USD) | 852.59M | ||
| Assets Non-Current | 8.20M | ||
| Total Debt (USD) | 72.00K | ||
| Trade and Non-Trade Payables | 7.72M | ||
| Tax Assets | 2.81M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 122.00K | ||
| Net Cash Flow from Financing | 3.64M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -92.41M | ||
| Capital Expenditure | -8.00K | ||
| Issuance (Purchase) of Equity Shares | 3.56M | ||
| Net Cash Flow from Investing | -8.00K | ||
| Net Cash Flow from Operations | -95.06M | ||
| Effect of Exchange Rate Changes on Cash | -988.00K | ||
| Share Based Compensation | 11.14M | ||